2022
Interaction between maternal killer immunoglobulin-like receptors and offspring HLAs and susceptibility of childhood ALL
Feng Q, Zhou M, Li S, Morimoto L, Hansen H, Myint SS, Wang R, Metayer C, Kang A, Fear AL, Pappas D, Erlich H, Hollenbach JA, Mancuso N, Trachtenberg E, de Smith AJ, Ma X, Wiemels JL. Interaction between maternal killer immunoglobulin-like receptors and offspring HLAs and susceptibility of childhood ALL. Blood Advances 2022, 6: 3756-3766. PMID: 35500222, PMCID: PMC9631572, DOI: 10.1182/bloodadvances.2021006821.Peer-Reviewed Original ResearchConceptsKiller immunoglobulin-like receptorsMaternal killer immunoglobulin-like receptorsAcute lymphoblastic leukemiaChild-mother pairsImmunoglobulin-like receptorsArginase IIKIR interactionsLower riskNon-Latino white subjectsLower tumor necrosisCase-control studyEtiology of childhoodDevelopment of childhoodHLA-KIRNeonatal cytokinesCytokine levelsCytokine profileLymphoblastic leukemiaImmune factorsImmune phenotypeTumor necrosisHigh riskChildhood leukemiaCytokine controlSignificant association
2021
Mode of Delivery, Birth Characteristics and Early-Onset Non-Hodgkin Lymphoma in a Population-Based Case-Control Study
Dwyer KE, Wang R, Cozen W, Cartmel B, Wiemels JL, Morimoto LM, Metayer C, Ma X. Mode of Delivery, Birth Characteristics and Early-Onset Non-Hodgkin Lymphoma in a Population-Based Case-Control Study. Cancer Epidemiology Biomarkers & Prevention 2021, 30: cebp.0535.2021. PMID: 34548330, DOI: 10.1158/1055-9965.epi-21-0535.Peer-Reviewed Original ResearchConceptsNon-Hodgkin lymphomaT-cell non-Hodgkin lymphomaCase-control studyBirth characteristicsMode of deliveryYear of birthOdds ratioNHL riskUnconditional multivariable logistic regression modelsPopulation-based case-control studyCases of NHLMultivariable logistic regression modelConfidence intervalsAge of diagnosisPediatric Burkitt lymphomaLogistic regression modelsCesarean sectionHistologic subtypeDecreased riskHodgkin's lymphomaMaternal ageBurkitt's lymphomaElevated riskLower riskMaternal education
2019
Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†
Davidoff AJ, Hu X, Bewersdorf JP, Wang R, Podoltsev NA, Huntington SF, Gore SD, Ma X, Zeidan AM. Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†. Leukemia & Lymphoma 2019, 61: 1178-1187. PMID: 31878809, PMCID: PMC7735409, DOI: 10.1080/10428194.2019.1703970.Peer-Reviewed Original ResearchConceptsHigh-risk myelodysplastic syndromeExcess blastsRefractory anemiaOverall survival benefitRetrospective cohort studyMedian OSOS benefitRAEB patientsCohort studySurvival benefitTherapy useMyelodysplastic syndromeClinical trialsLower riskMedicare dataPatientsPropensity scoreOlder adultsDiagnosisAnemiaQuartileUnited StatesAssociationEnd resultOS